Senzime in brief
Senzime develops and markets CEmarked and FDA-approved medical device systems driven by unique algorithms and disposable sensors that evaluate patient muscle function before, during and after surgery under anesthetic.
The company’s goal is to contribute to improved clinical precision and simplified management of health care. Senzime’s solution is called TetraGraph®, which digitally and continuously measures the level of neuromuscular blockade to prevent complications. Fewer complications mean less suffering for patients, but also help shorten hospitalizations, and reduce the cost of care.
Senzime’s vision is for TetraGraph® to be deployed in every surgical procedure where neuromuscular blocking agents (NMBAs) are used, to enable safe emergence from anesthesia for all patients.
The global challenge
Seventy years after the introduction of NMBAs in anesthesia practice, anesthesiologists still face challenges in the correct management of neuromuscular blockade postoperatively.
6 OUT OF 10 PATIENTS
are incompletely reversed on extubation, a
condition known as residual neuromuscular
blockade, RNMB.
93 PERCENT
of patients affected by a serious critical
complication have RNMB.
22 MILLION PATIENTS
are affected by critical complications on waking
from anesthesia.
≈$1,500 PER DAY
could be saved by avoiding patients needing
intensive care becaused of RNMB.